Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARDS (Acute Respiratory Distress Syndrome) Clear all
Recruiting Phase 2 Interventional

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Atibuclimab, Placebo
Biological · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 3 Interventional Results available

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome

NCT00244101
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
PS Group, NCPAP Group, ISX Group
Drug · Device
Lead sponsor
Vermont Oxford Network
Network
Eligibility
26 Weeks to 29 Weeks
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 14, 2026, 12:22 PM EDT
Suspended Phase 2 Interventional

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

NCT04056741
View directory record Official record
Conditions
RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
Interventions
surfactant airway device
Combination Product
Lead sponsor
ONY
Industry
Eligibility
24 Weeks and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
San Diego, California • St. Petersburg, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 14, 2026, 12:22 PM EDT
Completed No phase listed Observational

Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials

NCT00719446
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

NCT04412057
View directory record Official record
Conditions
COVID-19 Pneumonia, Acute Lung Injury, ARDS
Interventions
CERC-002, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Newport Beach, California • Ft. Pierce, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 14, 2026, 12:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 14, 2026, 12:22 PM EDT
Completed No phase listed Observational

A Retrospective Study of COVID-19 Treatments

NCT04949230
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Lower Respiratory Infection, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
No Intervention Used
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 14, 2026, 12:22 PM EDT
Not listed Not applicable Interventional

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

NCT04669444
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication, Respiratory Failure, Renal Failure, Critical Illness, Pulmonary Disease
Interventions
Ventilator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 14, 2026, 12:22 PM EDT
Completed No phase listed Observational

Electrical Activity of Diaphragm as a Means to Predict Extubation Success in Preterm Infants

NCT02144363
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
1 Hour to 28 Days
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 14, 2026, 12:22 PM EDT
Recruiting Not applicable Interventional

The ARISE Study - Use of Vertical Positioning

NCT07025421
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Intervention Upright Bed positioning
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Phase 1 Interventional

Seattle-PAP Bubble Nasal CPAP and Work of Breathing

NCT02210026
View directory record Official record
Conditions
Respiratory Distress Syndrome In Premature Infants, Bronchopulmonary Dysplasia, Newborn Primary Sleep Apnea
Interventions
Seattle-PAP
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Hours to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 14, 2026, 12:22 PM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Not applicable Interventional

Adaptive Support Ventilation in Acute Respiratory Distress Syndrome

NCT03715751
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
ASV, Lung Protective Ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 14, 2026, 12:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Drug Study of Albuterol to Treat Acute Lung Injury

NCT00434993
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 14, 2026, 12:22 PM EDT
Suspended Phase 2 Interventional

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

NCT04482621
View directory record Official record
Conditions
COVID-19
Interventions
Decitabine, Placebo Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 14, 2026, 12:22 PM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 14, 2026, 12:22 PM EDT
Withdrawn Not applicable Interventional

Titration of PEEP During Mechanical Ventilation in Patients With ARDS Using Electrical Impedance Tomography.

NCT02596178
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Electrical Impedance Tomography
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 14, 2026, 12:22 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 14, 2026, 12:22 PM EDT
Completed No phase listed Observational

Local Assessment of Ventilatory Management During General Anesthesia for Surgery

NCT01601223
View directory record Official record
Conditions
Surgery, Anaesthesia, Ventilator-Induced Lung Injury, Lung Injury, Pneumonia, Pneumothorax, Respiratory Distress Syndrome, Adult, Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
European Society of Anaesthesiology
Other
Eligibility
18 Years and older
Enrollment
10,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 14, 2026, 12:22 PM EDT
Completed Not applicable Interventional

Fluid Restriction in Respiratory Distress of the Newborn

NCT03120585
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Fluid Management Intervention
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 12 Hours
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • Lawton, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 14, 2026, 12:22 PM EDT
Recruiting Not applicable Interventional

Vascular ARDS Recruitment After Inhaled Nitric Oxide

NCT05801224
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions
Nitric Oxide
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 12:22 PM EDT